FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281686449> ?p ?o ?g. }

• W4281686449 endingPage "e19505" @default.
• W4281686449 startingPage "e19505" @default.
• W4281686449 abstract "e19505 Background: Receptor tyrosine kinase-like Orphan Receptor-1 (ROR1) is widely expressed on hematological and solid tumors. NVG-111, a first in class humanized tandem scFv ROR1xCD3 bispecific antibody elicits potent killing of ROR1 + tumor cells in vitro and in vivo. This bispecific T-cell engager (TCE) is being evaluated in a first in human, Phase I trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The predicted therapeutic dose and steady state serum concentrations of NVG-111 were estimated by allometric scaling using relevant doses from a murine PK study. To assess free drug levels in patients following 21 days of continuous infusion of NVG-111, a bespoke, sensitive pharmacokinetics (PK) assay with high levels of specificity and sensitivity was developed. Methods: Anti-idiotype (anti-ID) antibodies directed to anti-ROR1 (αROR1-ID) and anti-CD3 (αCD3-ID) were generated by mouse immunization or by phage display from customized libraries. A proof-of-concept sandwich ELISA assay was developed using αCD3-ID to capture NVG-111 and detection by biotinylated hROR1-streptavidin-HRP. Gyrolab and Quanterix Simoa high sensitivity ELISA platforms were used to detect NVG-111 by αCD3-ID capture and αROR1-ID detection. The mesoscale discovery electrochemiluminescence assay (MSD-ECLA) was developed using a reversed format; NVG-111 capture with αROR1-ID and detection with αCD3-ID. Results: Allometric scaling predicted a theoretically relevant therapeutic dose and steady state serum concentration of 1ng/mL NVG-111 in humans, which was just at the level of sensitivity of a conventional ELISA under non-matrix conditions. Transferring the format to Quanterix Simoa had limited success due to high background levels in all configurations evaluated. The Gyrolab platform increased sensitivity to 75pg/mL, but suboptimal individual human sera matrix selectivity limited assay validity. Assessment of MSD-ECLA provided the best signal/noise, enhanced human disease and healthy sera selectivity, and a dynamic sensitivity range of 250pg/mL to 32ng/mL, which enabled the development of a GCLP qualified PK assay. The MSD-ECLA assay was employed to measure NVG-111 concentrations in CLL or MCL subjects dosed with 0.3-30µg/day NVG-111. MSD-ECLA detected drug in patients receiving NVG-111, with a range of steady-state serum concentrations (C avg.ss ) of 168-610pg/mL. This was in-line with the predicted drug levels from the single species allometric scaling, albeit with observed levels being marginally lower than expected. Conclusions: Development, custom optimization and validation of a highly sensitive MSD-ECLA PK assay has enabled GCLP-compliant measurement of circulating NVG-111 in CLL or MCL patients treated with at least 10µg/day cIV NVG-111." @default.
• W4281686449 created "2022-06-13" @default.
• W4281686449 creator A5009899145 @default.
• W4281686449 creator A5013156007 @default.
• W4281686449 creator A5013238164 @default.
• W4281686449 creator A5032635874 @default.
• W4281686449 creator A5038263540 @default.
• W4281686449 creator A5045434240 @default.
• W4281686449 creator A5059796399 @default.
• W4281686449 creator A5066475421 @default.
• W4281686449 creator A5067537664 @default.
• W4281686449 creator A5074465192 @default.
• W4281686449 creator A5079438937 @default.
• W4281686449 creator A5080237909 @default.
• W4281686449 date "2022-06-01" @default.
• W4281686449 modified "2023-09-27" @default.
• W4281686449 title "A sensitive and robust bioanalytical assay for pharmacokinetic analysis of ROR1xCD3 bispecific T cell engager (NVG-111) in a first-in-human study." @default.
• W4281686449 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e19505" @default.
• W4281686449 hasPublicationYear "2022" @default.
• W4281686449 type Work @default.
• W4281686449 citedByCount "0" @default.
• W4281686449 crossrefType "journal-article" @default.
• W4281686449 hasAuthorship W4281686449A5009899145 @default.
• W4281686449 hasAuthorship W4281686449A5013156007 @default.
• W4281686449 hasAuthorship W4281686449A5013238164 @default.
• W4281686449 hasAuthorship W4281686449A5032635874 @default.
• W4281686449 hasAuthorship W4281686449A5038263540 @default.
• W4281686449 hasAuthorship W4281686449A5045434240 @default.
• W4281686449 hasAuthorship W4281686449A5059796399 @default.
• W4281686449 hasAuthorship W4281686449A5066475421 @default.
• W4281686449 hasAuthorship W4281686449A5067537664 @default.
• W4281686449 hasAuthorship W4281686449A5074465192 @default.
• W4281686449 hasAuthorship W4281686449A5079438937 @default.
• W4281686449 hasAuthorship W4281686449A5080237909 @default.
• W4281686449 hasConcept C112705442 @default.
• W4281686449 hasConcept C153911025 @default.
• W4281686449 hasConcept C159654299 @default.
• W4281686449 hasConcept C185592680 @default.
• W4281686449 hasConcept C203014093 @default.
• W4281686449 hasConcept C204628709 @default.
• W4281686449 hasConcept C2776190903 @default.
• W4281686449 hasConcept C2777938653 @default.
• W4281686449 hasConcept C2778020697 @default.
• W4281686449 hasConcept C2778204606 @default.
• W4281686449 hasConcept C2778461978 @default.
• W4281686449 hasConcept C2778957590 @default.
• W4281686449 hasConcept C3020495827 @default.
• W4281686449 hasConcept C502942594 @default.
• W4281686449 hasConcept C542903549 @default.
• W4281686449 hasConcept C55493867 @default.
• W4281686449 hasConcept C71924100 @default.
• W4281686449 hasConcept C86803240 @default.
• W4281686449 hasConcept C98274493 @default.
• W4281686449 hasConceptScore W4281686449C112705442 @default.
• W4281686449 hasConceptScore W4281686449C153911025 @default.
• W4281686449 hasConceptScore W4281686449C159654299 @default.
• W4281686449 hasConceptScore W4281686449C185592680 @default.
• W4281686449 hasConceptScore W4281686449C203014093 @default.
• W4281686449 hasConceptScore W4281686449C204628709 @default.
• W4281686449 hasConceptScore W4281686449C2776190903 @default.
• W4281686449 hasConceptScore W4281686449C2777938653 @default.
• W4281686449 hasConceptScore W4281686449C2778020697 @default.
• W4281686449 hasConceptScore W4281686449C2778204606 @default.
• W4281686449 hasConceptScore W4281686449C2778461978 @default.
• W4281686449 hasConceptScore W4281686449C2778957590 @default.
• W4281686449 hasConceptScore W4281686449C3020495827 @default.
• W4281686449 hasConceptScore W4281686449C502942594 @default.
• W4281686449 hasConceptScore W4281686449C542903549 @default.
• W4281686449 hasConceptScore W4281686449C55493867 @default.
• W4281686449 hasConceptScore W4281686449C71924100 @default.
• W4281686449 hasConceptScore W4281686449C86803240 @default.
• W4281686449 hasConceptScore W4281686449C98274493 @default.
• W4281686449 hasIssue "16_suppl" @default.
• W4281686449 hasLocation W42816864491 @default.
• W4281686449 hasOpenAccess W4281686449 @default.
• W4281686449 hasPrimaryLocation W42816864491 @default.
• W4281686449 hasRelatedWork W1500653567 @default.
• W4281686449 hasRelatedWork W1964314546 @default.
• W4281686449 hasRelatedWork W1972347968 @default.
• W4281686449 hasRelatedWork W1974363859 @default.
• W4281686449 hasRelatedWork W2030621571 @default.
• W4281686449 hasRelatedWork W2368460920 @default.
• W4281686449 hasRelatedWork W4235288995 @default.
• W4281686449 hasRelatedWork W4281686449 @default.
• W4281686449 hasRelatedWork W2517161749 @default.
• W4281686449 hasRelatedWork W4290228479 @default.
• W4281686449 hasVolume "40" @default.
• W4281686449 isParatext "false" @default.
• W4281686449 isRetracted "false" @default.
• W4281686449 workType "article" @default.